Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 21, 2015, Pages 6607-6612

  Xue, Shenghui ^a   Yang, Hua ^b   Qiao, Jingjuan ^a,c   Pu, Fan ^a,c   Jiang, Jie ^a   Hubbard, Kendra ^a   Hekmatyar, Khan ^d   Langley, Jason ^e   Salarian, Mani ^a   Long, Robert C ^b   Bryant, Robert G ^f   Hu, Xiaoping Philip ^e   Grossniklaus, Hans E ^b   Liu, Zhi Ren ^a   Yang, Jenny J ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Inlighta Biosciences LLC   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e Emory University   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Contrast agents; Metastasis; MRI; T2< inf> T1< inf> ratio imaging; Uveal melanoma

Indexed keywords

CALCIUM; CHELATING AGENT; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOXETIC ACID; MAGNESIUM; METAL; METAL CHELATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PARVALBUMIN; PENTETIC ACID; PROCA32; UNCLASSIFIED DRUG; ZINC; CONTRAST MEDIUM; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER SIZE; CHELATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG PROTEIN BINDING; EARLY DIAGNOSIS; HUMAN; IN VIVO STUDY; LIMIT OF DETECTION; LIVER METASTASIS; LIVER SINUSOID; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; RAT; SELECTIVITY AND SENSITIVITY; SENSITIVITY AND SPECIFICITY; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; LIVER NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; PROTEIN STABILITY; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; GADOLINIUM; LIMIT OF DETECTION; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PARVALBUMINS; PROTEIN ENGINEERING; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 84930226634     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423021112     Document Type: Article

References (33)

1. Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11(6):479-497.
2. Van den Eynden GG, et al. (2013) The multifaceted role of the microenvironment in liver metastasis: Biology and clinical implications. Cancer Res 73(7):2031-2043.
3. Sato T (2010) Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 37(2):127-138.
4. Grossniklaus HE (2013) Progression of ocular melanoma metastasis to the liver: The 2012 Zimmerman Lecture. JAMA Ophthalmol 131(4):462-469.
5. Arzumanyan A, Reis HM, Feitelson MA (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13(2):123-135.
6. Cárdenas-Rodríguez J, Howison CM, Matsunaga TO, Pagel MD (2013) A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents. Magn Reson Imaging 31(6):900-910.
7. Yankeelov TE, Abramson RG, Quarles CC (2014) Quantitative multimodality imaging in cancer research and therapy. Nat Rev Clin Oncol 11(11):670-680.
8. Major JL, Meade TJ (2009) Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res 42(7):893-903.
9. Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H (2003) Tissue-specific MR contrast agents. Eur J Radiol 46(1):33-44.
10. Yang JJ, et al. (2008) Rational design of protein-based MRI contrast agents. J Am Chem Soc 130(29):9260-9267.
11. Xue S, et al. (2014) Design of ProCAs (protein-based Gd3+ MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers. Med Res Rev 34(5):1070-1099.
12. Xue S, Qiao J, Pu F, Cameron M, Yang JJ (2013) Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5(2):163-179.
13. Qiao J, et al. (2014) Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem 19(2):259-270.
14. Yang W, et al. (2005) Design of a calcium-binding protein with desired structure in a cell adhesion molecule. J Am Chem Soc 127(7):2085-2093.
15. Li S, et al. (2012) PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities. J Inorg Biochem 107(1):111-118.
16. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 43(12):817-828.
17. Caravan P, Farrar CT, Frullano L, Uppal R (2009) Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganesebased T1 contrast agents. Contrast Media Mol Imaging 4(2):89-100.
18. Ananta JS, et al. (2010) Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol 5(11): 815-821.
19. Diakova G, Goddard Y, Korb JP, Bryant RG (2011) Water-proton-spin-lattice-relaxation dispersion of paramagnetic protein solutions. J Magn Reson 208(2): 195-203.
20. Lipari G, Szabo A (1982) Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J Am Chem Soc 104(17):4546-4559.
21. Polnaszek CF, Bryant RG (1984) Nitroxide radical induced solvent proton relaxation: Measurement of localized translational diffusion. J Chem Phys 81(9):4038-4045.
22. Kuruppu D, Christophi C, O'Brien PE (1997) Microvascular architecture of hepatic metastases in a mouse model. HPB Surg 10(3):149-157; discussion 158.
23. Yang H, et al. (2008) In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res 18(2):95-103.
24. Lattier JM, Yang H, Crawford S, Grossniklaus HE (2013) Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clin Exp Metastasis 30(8):969-976.
25. Winter PM, et al. (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108(18): 2270-2274.
26. Guo K, et al. (2010) Near infrared-fluorescent and magnetic resonance imaging molecular probe with high T1 relaxivity for in vivo multimodal imaging. Chem Commun (Camb) 46(21):3705-3707.
27. Caravan P, Greenwood JM, Welch JT, Franklin SJ (2003) Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem Commun (Camb) (20): 2574-2575.
28. Datta A, Raymond KN (2009) Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res 42(7):938-947.
29. Shapiro MG, et al. (2010) Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. Nat Biotechnol 28(3):264-270.
30. De Leon-Rodriguez LM, et al. (2009) Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 42(7):948-957.
31. Louie AY, et al. (2000) In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18(3):321-325.
32. Fulton DA, et al. (2006) Glycoconjugates of gadolinium complexes for MRI applications. Chem Commun (Camb) (10):1064-1066.
33. Cavé A, Daures MF, Parello J, Saint-Yves A, Sempere R (1979) NMR studies of primary and secondary sites of parvalbumins using the two paramagnetic probes Gd (III) and Mn (II). Biochimie 61(7):755-765.